Quality of life after therapeutic mammoplasty  by Haq, Iram et al.
Abstracts / International Journal of Surgery 10 (2012) 641e645 643
ABSTRACTSto determine the functional health status of patients who had undergone
the procedure.
Methods: The study included 189 patients undergoing the procedure
between 1983 and 2010, 78 females and 111males (mean age 8.39 years). A
child health questionnaire CHQ-PF50 was ﬁlled in by the parents. The
scores were transformed into a 0-100 scale and divided into physical and
psychosocial functioning. Data was collected by reviewing hospital records
and analysis carried out with the JMP statistical software.
Results: The group of respondents was 25 out of 100, out of which 15
identiﬁed patients. 14 patients from the whole cohort were deceased. The
highest score of the physical (PhS) functioning: 76.27, the psychosocial
(PsS) functioning: 62.44. The lowest score for the PhSwas 16.03 and for PsS
11.43. Mean score for PhS was 40.05 and for PsS 47.34. The median years
after the Fontan operation: 3.6 years and the median age: 4.4 years. The
results show the mean PhS being below the average for the general U.S
population while just below the average in PsS.
Conclusions: The functional health outcome of patients after the Fontan
operation is below the average in a physical aspect and just below the
average psychosocially.
Considering it is a complex congenital heart disease this might bewhat can
be expected from these individuals.
Keywords: Cardiac surgery, Single ventricle, Fontan procedure, Functional
health outcome
ENDOSCOPIC PALLIATION OF MALIGNANT BILIARY OBSTRUCTION. ARE
METAL STENTS WORTH THE COST?
Hayley Heffernan, Irina Baimatova, Gemma Gossedge, Mike Zeiderman.
Southport District General Hospital, United Kingdom
Introduction: This study was designed to determine whether the use of
plastic stents should be abandoned on the basis of effectiveness and cost.
Method: The records of all patients with malignant biliary obstruction,
who underwent ERBD at Southport Hospital between 2005 and 2010, were
reviewed. Patients with nonmalignant biliary obstruction, obstruction due
to other primary malignancies and those lost to follow up were excluded.
The incidence of complications, patency rates, readmissions and time
spent in hospital were recorded. Cost was calculated from NHS tariff of
ERCP + plastic stent at £835 and metal stent at £1496.
Results: 49 patients were included. M:F 27:22. Median age 77 years (range
59e96). 46 patients had plastic stents and 3 had metal stents inserted.
Diagnoses e pancreatic carcinoma (36), cholangiocarcinoma (8), ampul-
lary carcinoma (5). Median bilirubin at time of ﬁrst ERCP e 301 mmol/L
(range 62e759).
There were no immediate procedure-related complications.
Eight patients (17%) represented with blocked plastic stents at a median
time of 80 days (range 3e280). Of these, 6 patients had a plastic and one
had a metal stent re-inserted.
If primary treatment had been with metal stents then the cost would have
been £73,304. Allowing for readmissions and stent changes, total cost for
the plastic stent group was £47,301, a saving of £26,003.
Conclusion: Plastic stents provide long-term palliation of ERBD for the
majority of patients and should be accepted as ﬁrst line treatment. The cost
of primary treatment with metal stents cannot be justiﬁed.
QUALITY OF LIFE AFTER THERAPEUTIC MAMMOPLASTY
Dr. Iram Haq, K.L. Kirkpatrick, G. Mitchell, A.P. Tansley. Mersey Foundation
School (FY1), United Kingdom
Aims: Therapeutic mammaplasty (TM) is increasingly used to treat breast
tumours where breast size allows; no data exists for subsequent Quality of
Life (QoL). This pilot study assessed QoL to provide evidence for TM as an
appropriate technique.
Methods: A QoL questionnaire was employed incorporating six validated
tools including the European Organisation for Research and Treatment of
Cancer QoL questionnaire for breast cancer, on patients undergoing TM
from 2006 to 2010. Cosmesis was judged by medical and non-medical
personnel.
Results: 46 patients (average BMI 30 kg/m2 (range 23e40)), underwent
TM, 96% for malignancy. Preoperative estimated breast volume was
226d2592 cm3 (mean 1061cm3), predicted percentage resection 0.8e35%(mean 10%); ultimate average resection was 258 g (36e1067 g). Compli-
cations predominantly fat necrosis, occurred in 24%, ﬁve patients required
completion mastectomy, 96% received adjuvant radiotherapy.
QoL scores (n¼36) were excellent with a mean of 73% [95% CI 68e78],
psychosexual function subset scored highest (83%). Mean cosmesis score
was 67% [95% CI 61e73], comparable with previously reported data. QoL
increased by 14% from 6 months to 3 years despite 10% cosmesis decline.
Conclusion: This study suggests good sustained QoL after TM, supporting
its use in selected patients. Mastectomy may not be avoided and coun-
seling should reﬂect this.
LONG TERM OUTCOMES OF CYCLODIODE THERAPY FOR RAISED
INTRAOCULAR PRESSURE AT A UK TEACHING HOSPITAL
Ivailo Zhekov. University of Cambridge Clinical School, United Kingdom
Aim: The main aims of this study were to investigate the dose-response
relation of the cyclodiode treatment and to evaluate possible predictive
factors that would help establish optimum parameters. The outcomes of
the procedure were evaluated both post-operatively and through long-
term follow-up.
Methods: A retrospective review of 87 patients who underwent trans-
scleral diode laser cyclophotocoagulation procedure from 2004 through
2011.
Results: Mean intraocular pressure (IOP) decreased signiﬁcantly from
39.54 mmHg (SE 1.26) before cyclodiode therapy to 17.83 mmHg (SE 1.51)
post-treatment, a reduction of 45.09% (p< 0.0001). This wasmeasured at 6
weeks andmaintained for 3 years. Pressure reduction of>30% of initial IOP
was achieved in 72.34% of the patients. This was greater (80.3%) in the
group receiving extensive treatment (90J). In addition, a signiﬁcant
proportion of the patients that underwent cyclodiode therapy (63.45%)
decreased their number of IOP lowering medications postoperatively from
2.56 to 1.59. Hypotony occurred in 5.31% of patients, predominantly in
patients receiving extensive treatment (90e120J), however none of the
patients developed further complications or required enucleation. Neo-
vascular glaucoma was a signiﬁcant risk factor. Visual acuity (VA)
remained unchanged or improved for the majority of the patients under-
going a cyclodiode procedure (83.55%) and was maintained long-term.
Conclusion: Cyclodiode therapy is a highly effective method for achieving
reduction of Intraocular Pressure and long-term maintenance of Visual
Acuity in patients with glaucoma.
A MULTICENTRE NATIONAL AUDIT OF THE RECORDING OF PATIENTS
WEIGHT: IMPLICATIONS FOR THE PRESCRIPTION OF GENTAMICIN
AND THERAPEUTIC-DOSE LOW MOLECULAR WEIGHT HEPARIN
Dr. Jamie Willson, Dr. Sebastian Thomas, Mr. Jonathan Horsnell, Dr.
Soumen Sen, Dr. Strachan Mackenzie, Dr. Arti Patel, Dr. William Ratliff,
Dr. Sabrina Black, Dr. Sarasvati Chauhan, Dr. Alice Armitage, G.P. Tarr, Dr.
Kathryn Garnham, Dr. Alistair Robb. Imperial College School of Medicine
(FY2), United Kingdom
Objectives: Identify the percentage of patients being weighed in hospital
and the proportion of these prescribed gentamicin or therapeutic dose low
molecular weight heparin (t-LMWH).
Design: Retrospective review of drug charts and bedside notes of all
secondary care hospital inpatients across 5 wards; 2medical, 2 surgery and
1 peadiatrics chosen at random in 11 hospitals in England and Wales.
Results: A total of 48.5% (515/1061) of hospital inpatients had their weight
recorded (paediatric wards 98% (77/78), adult wards 45.8% (438/983)). The
range of recording between hospitals was 23.0% and 93.3%. In total 113
patients audited were receiving either Gentamicin of t-LMWH; 65.2% (73/
113) of which had a recorded weight. Of those receiving t-LMWH: 74.2%
(49/66) were weighed vs 56.6% (30/53) of those receiving Gentamicin.
There was large variation between hospitals in recording weight of
patients receiving Gentamicin or t-LMWH, 25.0%e100% (1/4e6/6).
Conclusions: Over half of the inpatients are not being weighed in hospital,
falling short of NICE and DoH guideline to weigh all hospital patients. This
failure leaves patients at risk of undetected malnutrition, which increases
the risk of mortality, post-operative complications and lengthened
hospitals stays. Furthermore, patient on drugs requiring a weight speciﬁc
dose, are at greater risk of severe side effects or subtherapeutic drug
